Zymeworks BC Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
12analysts covering
FY EPS (est.)
$1.12next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly403.8MTarget: Maintain sufficient liquidity to fund operations beyond 2028
Ziihera (zanidatamab) Royalty Revenue Quarterly900KTarget: Long-term growth driven by global commercialization and market penetration
Adjusted Gross Operating Expenses (Non-GAAP) Annually49.5MTarget: Approximately 20% lower in FY 2026 compared to FY 2025 ($170.5 million)
Watch Items
- FDA PDUFA Target Action Date for Zanidatamab in 1L HER2-Positive GEATrigger: August 25, 2026Action: Monitor FDA decision; approval triggers a $250.0 million milestone payment from partner Jazz Pharmaceuticals.
- ZW191 Phase 1 Dose Optimization and Expansion CohortsTrigger: Presentation of mature clinical data at major medical meetings in 2026Action: Evaluate objective response rates (ORR) and progression-free survival (PFS) in folate receptor alpha-expressing ovarian and endometrial cancers.
- ZW251 Phase 1 Clinical Trial RecruitmentTrigger: Active recruitment of patients with GPC3-expressing hepatocellular carcinomaAction: Track safety, tolerability, and initial efficacy signals of the GPC3-targeting ADC.
Research as of 20 Jun 2026